Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia

Experimental Hematology

Volumn 58, Issue , 2018, Pages 52-58

  Gregory, Mark A ^a   Nemkov, Travis ^a   Reisz, Julie A ^a   Zaberezhnyy, Vadym ^a   Hansen, Kirk C ^a   D'Alessandro, Angelo ^a   DeGregori, James ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CB 839; GLUTAMIC ACID; GLUTAMINASE; GLUTAMINE; GLUTATHIONE; HYDROLASE INHIBITOR; QUIZARTINIB; REACTIVE OXYGEN METABOLITE; TRACER; UNCLASSIFIED DRUG; BENZENEACETAMIDE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; CARBANILAMIDE DERIVATIVE; CB-839; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; THIADIAZOLE DERIVATIVE;

ACUTE MYELOID LEUKEMIA; ACUTE MYELOID LEUKEMIA CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GLUTATHIONE METABOLISM; IN VIVO STUDY; METABOLIC FLUX ANALYSIS; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; BENZENEACETAMIDES; BENZOTHIAZOLES; CELL LINE, TUMOR; FEMALE; FMS-LIKE TYROSINE KINASE 3; GLUTAMIC ACID; GLUTAMINASE; GLUTAMINE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; PHENYLUREA COMPOUNDS; THIADIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85032893031     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2017.09.007     Document Type: Article

References (18)

1. Bose, P., Vachhani, P., Cortes, J.E., Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat Options Oncol, 18, 2017, 17.
2. De Kouchkovsky, I., Abdul-Hay, M., Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J, 6, 2016, e441.
3. Small, D., FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program, 2006, 178–184.
4. Papaemmanuil, E., Gerstung, M., Bullinger, L., et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374 (2016), 2209–2221.
5. Pratz, K.W., Luger, S.M., Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?. Curr Opin Hematol 21 (2014), 72–78.
6. Glasauer, A., Chandel, N.S., Targeting antioxidants for cancer therapy. Biochem Pharmacol 92 (2014), 90–101.
7. Wondrak, G.T., Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 11 (2009), 3013–3069.
8. Pei, S., Minhajuddin, M., Callahan, K.P., et al. Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem 288 (2013), 33542–33558.
9. Gregory, M.A., D'Alessandro, A., Alvarez-Calderon, F., et al. ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. Proc Natl Acad Sci USA 113 (2016), E6669–E6678.
10. Auclair, D., Miller, D., Yatsula, V., et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 21 (2007), 439–445.
11. Quentmeier, H., Martelli, M.P., Dirks, W.G., et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 19 (2005), 1760–1767.
12. Alvarez-Calderon, F., Gregory, M.A., Pham-Danis, C., et al. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clin Cancer Res 21 (2015), 1360–1372.
13. Nemkov, T., Hansen, K.C., D'Alessandro, A., A three-minute method for high-throughput quantitative metabolomics and quantitative tracing experiments of central carbon and nitrogen pathways. Rapid Commun Mass Spectrom 31 (2017), 663–673.
14. D'Alessandro, A., Amelio, I., Berkers, C.R., et al. Metabolic effect of TAp63alpha: enhanced glycolysis and pentose phosphate pathway, resulting in increased antioxidant defense. Oncotarget 5 (2014), 7722–7733.
15. Willems, L., Jacque, N., Jacquel, A., et al. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 122 (2013), 3521–3532.
16. Jacque, N., Ronchetti, A.M., Larrue, C., et al. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood 126 (2015), 1346–1356.
17. Matre, P., Velez, J., Jacamo, R., et al. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget 7 (2016), 79722–79735.
18. Goto, M., Miwa, H., Shikami, M., et al. Importance of glutamine metabolism in leukemia cells by energy production through TCA cycle and by redox homeostasis. Cancer Invest 32 (2014), 241–247.